Alnylam Reports Positive Topline Results from ILLUMINATE-B Phase 3 Study of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 in Children Under the Age of Six
Retrieved on:
Wednesday, September 30, 2020
Research, Children, Genetics, Clinical trials, Other Health, Biotechnology, Pharmaceutical, Consumer, Health, Science, Branches of biology, Hyperoxaluria, RNA, Primary hyperoxaluria, Hydroxyacid oxidase (glycolate oxidase) 1, RNA interference, Acid Pro, PH1b, RNAI, Biology, Molecular biology, ILLUMINATE-A Phase 3 Study, Lumasiran, Primary Hyperoxaluria Type 1 (PH1), RNAi, Alnylam Pharmaceuticals
We are pleased to report these positive topline results that we believe hold promise for many families impacted by PH1.
Key Points:
- We are pleased to report these positive topline results that we believe hold promise for many families impacted by PH1.
- We look forward to reporting complete data from the ILLUMINATE-B study at the ASN virtual congress later this fall.
- The ILLUMINATE-B results signal hope for the many families with children whose lives are deeply impacted by PH1.
- Lumasiran is an investigational, subcutaneously administered RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) in development for the treatment of primary hyperoxaluria type 1 (PH1).